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What’s new? 
 The 2016 National Pregnancy in Diabetes audit demonstrates little change in 
pregnancy preparation or outcomes and substantial clinic-to-clinic variations in care. 
 Reproductive health needs to be as integrated into the diabetes care plans of women 
with diabetes as retinal screening or annual reviews. 
 Awareness raising about pre-pregnancy care could be improved in primary care 
settings using mobile technology, information prescriptions and electronic templates. 
 As device usability improves, closed-loop and automated insulin delivery systems 
may help to minimize the impact of clinic-to-clinic variations. 
 
Abstract 
Our aim was to review the data from the National Pregnancy in Diabetes (NPID) audit, and to 
identify the challenges and opportunities for improving pregnancy outcomes in women with 
diabetes. We reviewed three years of NPID data and relevant diabetes and obstetric literature, 
and found that there has been little change in pregnancy preparation or outcomes over the 
past 3 years, with substantial clinic-to clinic variations in care. Women with Type 2 diabetes 
remain less likely to take 5 mg preconception folic acid (22.8% vs. 41.8%; P < 0.05), and 
more likely to take potentially harmful medications (statin and/or ACE inhibitor 13.0% vs. 
1.8%; P < 0.05) than women with Type 1 diabetes. However, women with Type 1 diabetes 
are less likely to achieve the recommended glucose control target of HbA1c < 48 mmol/mol 
(6.5%) (14.9% vs. 38.1%; P < 0.05). The following opportunities for improvement were 
identified. First, the need to integrate reproductive health into the diabetes care plans of all 
women with diabetes aged 15–50 years. Second, to develop more innovative approaches to 
improve uptake of pre-pregnancy care in women with Type 2 diabetes in primary care 
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settings. Third, to integrate insulin pump, continuous glucose monitoring and automated 
insulin delivery technologies into the pre-pregnancy and antenatal care of women with Type 
1 diabetes. Fourth, to improve postnatal care with personalized approaches targeting women 
with previous pregnancy loss, congenital anomaly and perinatal mortality. A nationwide 
commitment to delivering integrated reproductive and diabetes healthcare interventions is 
needed to improve the health outcomes of women with diabetes. 
<H1>Background 
The National Pregnancy in Diabetes (NPID) audit was developed from existing regional 
diabetes in pregnancy networks and paper-based audits, in response to the Confidential 
Enquiry into Maternal and Child Health of 2002–2003, which quantified the potentially 
preventable poor pregnancy outcomes in women with diabetes [1–3]. 
In consultation with key stakeholders from diabetes, obstetrics, public health, midwifery and 
nursing services, and including women with diabetes, the following three questions were 
identified. First, were women with diabetes adequately prepared for pregnancy? Second, were 
appropriate steps taken to minimize adverse outcomes to the mother? Third, were appropriate 
steps taken to minimize adverse outcomes to the baby? These questions were closely aligned 
with the standards set out in the National Institute for Health and Clinical Excellence (NICE) 
clinical guidelines [4]. 
A two-stage ‘proof of concept’ validation study was undertaken. Retrospective data including 
consecutive pregnancies for 1381 women from three existing regional networks were used to 
identify the minimum standard dataset to answer the audit questions [1]. These were refined, 
tested for transferability and feasibility of collection across new maternity units who had not 
previously participated in regional audits [2]. With advances in technology, paper-based data 
forms were replaced by online data-collection systems. Prospective data using a standard 
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dataset that met the NHS Digital data standards were collected. Improved IT infrastructures 
allowed data from the National Diabetes Audit (NDA), Hospital Episode Statistics (HES), 
Patient Episode database for Wales (PEDW) and existing congenital anomaly registers to be 
incorporated, reducing the burden of local data collection. 
The NPID audit was launched as a part of the NDA portfolio with data collection from June 
2013 across England, Wales and the Isle of Man. Each annual cycle of data is reported in 
October–November of the following year, to ensure the data are contemporaneous and 
relevant to current clinical care. 
The purpose is to provide the metrics needed to benchmark care and outcomes in relation to 
NICE guidelines at a local, regional and national level. This also allows individual units, and 
regions to measure the impact of differences or changes in practice. All maternity units that 
are delivering women with pre-gestational diabetes are expected to contribute with increasing 
participation of women (1697 to 3297) and of units (128 to 172) between 2013 and 2016. As 
participation in the audit approaches full inclusion, we can better understand both the 
opportunities and the challenges for improving pregnancy outcomes. 
<H1>The changing demography of diabetes in pregnancy 
There has been a significant increase in the proportion of pregnant women with Type 2 
diabetes from 27% in 2002–2003 to 50% currently [5]. During 2016 there were, for the first 
time, more babies born to women with Type 2 diabetes than to women with Type 1 diabetes 
(Table 1). Some metropolitan centres now have > 70% of diabetes pregnancies in women 
with Type 2 diabetes. Nearly half of women with Type 2 diabetes are of Asian, Afro-
Caribbean or mixed ethnicity, meaning that 90% of Asian and 70% of Afro-Caribbean 
diabetes pregnancies are in women with Type 2 diabetes [5]. As has been previously 
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reported, women with Type 2 diabetes are more likely to come from areas of social 
deprivation, be older, have higher BMI and have shorter duration of diabetes [6]. 
This means that an increasing proportion of women have their routine diabetes care delivered 
outside specialist settings, where awareness of the specific issues of safe effective 
contraception and the risks of pregnancy associated with diabetes is limited. This leads to 
misconceptions and low levels of awareness among women of reproductive years with 
inadequate contraception to avoid unintended pregnancy and limited specific information to 
support optimal pregnancy preparation. Structured education programmes for Type 2 diabetes 
typically focus on older age groups, and do not routinely include contraception, the particular 
challenges of finding appropriate contraception for older women with higher BMI, and often 
additional cardiovascular risk factors, and the importance of pregnancy preparation. There 
may also be additional cultural and ethnic barriers to accessing contraception, that need to be 
overcome for women with Type 2 diabetes. 
<H1>Preparation for pregnancy 
Pregnancy is challenging for women with diabetes, as hyperglycaemia at any stage is 
associated with increased risk of complications for both mother and baby [7]. Early 
pregnancy (the first 6–7 weeks) is particularly crucial, as this is when organogenesis occurs. 
Hyperglycaemia in early pregnancy, lack of folic acid supplementation and taking potentially 
harmful diabetes medications, may all contribute to increased rates of congenital 
malformation [8]. In addition, before 8 weeks, women may not yet be aware that they are 
pregnant, and hence do not act to ameliorate the risks. Thus, the NICE guidelines recommend 
that all women with diabetes need either safe effective contraception to avoid an unintended 
pregnancy, or pre-pregnancy care to reduce diabetes-related risk factors before conception 
[4]. 
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Three key measures of pre-pregnancy care are captured in the NPID audit. These are use of 
5 mg folic acid, use of potentially harmful medications (statins, ACE inhibitors and glucose-
lowering medication other than insulin or metformin) before pregnancy, and maternal HbA1c 
level, targeting < 48 mmol/mol (6.5%) at the first antenatal visit. 
The benefits of pre-pregnancy care are well established, with fewer adverse maternal–fetal 
outcomes among women who are prepared for pregnancy compared with those who are not 
[9–12]. However, less than half of women with diabetes attend pre-pregnancy care [5]. 
Women with Type 1 diabetes are more likely to take 5 mg folic acid before pregnancy 
(41.8% vs. 22.8%) (Fig. 1) and less likely to take potentially harmful medications (statin 
and/or ACE inhibitor 1.8% vs. 13.0%), than women with Type 2 diabetes [5]. 
The glycaemic control target of HbA1c < 48 mmol/mol (6.5%) is achieved by only a minority 
of women with diabetes. Women with Type 2 diabetes are more than twice as likely to 
achieve this target (38.1% vs. 14.9%) than women with Type 1 diabetes. Women with greater 
levels of social deprivation are less likely to achieve this target. Worryingly, 12.5% of 
women with Type 1 and 7.4% of women with Type 2 diabetes have HbA1c levels 
> 86 mmol/mol, carrying an ~ 10% risk of serious adverse pregnancy outcome
 
[5]. 
The implications of these findings are that, although women with Type 2 diabetes have better 
glucose control, their behaviours around folic acid supplementation, use of potentially 
harmful medications and delayed presentation for antenatal care suggests that they are often 
poorly informed about the risks of diabetes in pregnancy, and what they can do to prepare for 
pregnancy. 
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<H1>Glucose control 
Data from successive NPID audits highlight the gap between the NICE glucose control 
targets, and what is achieved in routine antenatal care. Women who achieve the 
recommended HbA1c targets in early pregnancy are older, with shorter duration of diabetes 
and are less likely to live in a deprived region [5]. More women using insulin pump therapy 
achieve target HbA1c levels in early pregnancy compared to women using multiple daily 
injection (MDI) (20% vs. 13%; P < 0.05). Data, collected over the 3-year period 2014–2016 
highlight the important role of potentially modifiable clinical factors [13]. Data from 
individual units show striking levels of clinic-to-clinic variation in the proportion of women 
with diabetes achieving target HbA1c levels, both in Type 1 and Type 2 diabetes. This clinic-
to-clinic variation persists, so that even in late pregnancy (after 24 weeks gestation) it ranges 
from 0% to 82% in Type 1 diabetes and from 43% to 100% in Type 2 diabetes (Fig. 2). This 
contributes to the one in two babies at risk of complications related to maternal 
hyperglycaemia. During 2016, the rates of large for gestational age infants, preterm delivery, 
and babies admitted for neonatal care remained high, especially in babies of mothers with 
Type 1 diabetes (47% large for gestational age, 43% preterm and 40% admitted for neonatal 
care). 
 
<H1>Risks of recurrent adverse outcomes in women with diabetes 
Audits such as NPID allow us to quantify, and monitor over time, the high risk of adverse 
pregnancy outcome associated with diabetes [2,6,14]. However, these cross-sectional data 
provide aggregate estimates for all pregnancies, and little is known about how the risks may 
change for an individual woman with each subsequent pregnancy. Most women experience 
more than one pregnancy over their reproductive years. Longitudinal studies suggest that, for 
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women without diabetes, the risk of a recurrent miscarriage, stillbirth and congenital anomaly 
are approximately doubled in a second pregnancy, if experienced in their first pregnancy [15–
17]. 
Tennant et al. [18] reported on the first and second pregnancies of 220 women with diabetes 
in northeast England (89% Type 1), aiming to quantify the risk of recurrence of adverse 
pregnancy outcome. In this study, 30.5% of first pregnancies had a serious adverse outcome, 
defined as miscarriage, congenital anomaly (6.4%), stillbirth or infant death. Although, the 
overall risk was much lower in second pregnancies (16.8%), the risk of a second adverse 
outcome remained more than doubled among women with an adverse outcome in the first 
pregnancy. This increased risk was confounded by non-modifiable risk factors such as 
maternal ethnicity, but there was a strong association with increased peri-conception HbA1c 
level. 
Tennant et al. [18] also explored whether preparation for pregnancy changed between the 
first and second pregnancies. Similar to NPID findings, pregnancy preparation was 
suboptimal, with less than a quarter of women achieving HbA1c < 53 mmol/mol (7%) and 
27% taking folic acid before their first pregnancy. Despite some improvement in preparation 
for the second pregnancy, in general, women who were better or poorly prepared for their 
first pregnancy, were also better or poorly prepared for their second pregnancy [18]. Hence, 
women with a previous adverse outcome were no more likely to prepare for the second 
pregnancy. Importantly, the median inter-pregnancy interval for these women was only 
12 months, suggesting a relatively short window of opportunity to optimize preparation for 
the next pregnancy. Providing enough information to support these women without 
overwhelming them with negativity can be particularly challenging; ‘She didn’t like the 
horror stories as she calls them; all the bad things that could happen’ [19]. 
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<H1>How to improve preconception care 
Pre-pregnancy care aims to identify and modify biomedical, behavioural and social risks to 
women's reproductive health and pregnancy outcomes through prevention of unintended 
pregnancy and appropriate risk management [20]. NICE and other international guidelines 
recommend that pre-pregnancy care be incorporated into routine diabetes consultations from 
adolescence onwards [4,21]. 
Interventions to enhance the uptake of pre-pregnancy care include education, information 
leaflets and clinic proformas, targeting both healthcare professionals and women with 
diabetes [9,10]. Most studies are implementing and evaluating the interventions concurrently, 
but lack longer term follow-up when the processes have ‘bedded-in’. The interventions target 
all women aged 16–50 years, with limited impact (between 27% and 33%) on pre-pregnancy 
care attendance. Therefore, although we have a good understanding of what care is needed, 
and when this should be delivered, the challenge remains about how best to improve uptake 
of pre-pregnancy care by those for whom it is relevant. A consistent finding is that women 
with Type 2 diabetes are less likely to attend pre-pregnancy care than women with Type 1 
diabetes [6,10,13,22]. This is particularly important as women with Type 2 diabetes represent 
an increasing proportion of those with pre-gestational diabetes and of those who are most 
likely to enter pregnancy unprepared [5]. 
Qualitative studies have sought to explore the pre-pregnancy care experiences of women with 
diabetes and of healthcare professionals [19,23,24]. A synthesis of these data has highlighted 
a dissonance in the approach to, understanding of and communication about pre-pregnancy 
care between the women and professionals [25]. Professionals focus on pregnancy and 
preconception care, rather than talking about sexual activity and use of effective methods of 
contraception. The average age of first sexual intercourse is 16 years, with a 13–14-year 
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interval (and a lot of sexual activity) before the average age of a first pregnancy. Likewise, 
the average woman has 2.3 children, and so information that is relevant to women’s 
reproductive intentions need to be relevant, personalized, updated and continued. 
Interactions between professionals and women with diabetes are weighted toward other 
agendas (annual reviews, retinal screening, etc.) and often do not elicit the women’s use of 
contraception or reproductive intentions [25]. Currently in the UK, women with Type 2 
diabetes are specifically disadvantaged, as pre-pregnancy care is not a remunerable indicator 
for primary care providers in the quality outcomes framework (QOF), which focuses on 
control of lipids, blood pressure and HbA1c. Similarly, pre-pregnancy care is not an important 
focus on the curricula of structured education programmes for Type 2 diabetes. 
Some areas within the UK have reconfigured their diabetes services with the explicit 
intention of bringing specialist healthcare professionals with an emphasis on pre-pregnancy 
care into community settings [26]. However, in general, pre-pregnancy care is fragmented, 
therefore concerted and innovative approaches are needed to integrate it into the routine care 
of women with diabetes [27]. Alternative strategies to improve women’s awareness of how to 
reduce the risks of unplanned pregnancy are emerging. Recent studies have focused on the 
use of multimedia technologies, namely interactive CD-ROM and DVDs [28–30]. Although 
data on the impact of these initiatives are limited, they are associated with an increase in the 
perceived benefits and attitudes to contraceptive use, as well as improvements in knowledge 
and increased intention to initiate a discussion about pre-pregnancy care [28–30]. 
Mobile health (mHealth) technology is another strategy to enhance the uptake of pre-
pregnancy care. It has been estimated that 90% of the world’s population has access to 
mobile networks, with smartphones, which have the capacity to run applications (apps), 
accounting for a substantial proportion of mobile devices. These advances have resulted in a 
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proliferation of healthcare education, decision-making support, and self-care monitoring apps 
[31]. The potential reach of this technology has important implications for raising awareness 
of and engagement with pre-pregnancy care. Evaluation of an app designed for pregnant 
women with diabetes reported that 75% of women had downloaded a locally developed app, 
with almost half having actively engaged with it before pregnancy [32]. Therefore, seizing on 
this shift towards greater use of mobile technology, awareness raising about pre-pregnancy 
care could be improved. A robust programme of awareness raising and education, for women 
with diabetes and healthcare professionals, is needed for the systematic integration of 
reproductive healthcare into the routine diabetes care of women with diabetes. 
<H1>Improving glucose control in Type 1 diabetes pregnancy 
Glucose monitoring is the cornerstone of diabetes self-management. For pregnant women 
using insulin, self-management requires painstaking attention to glucose monitoring, with at 
least 7–10 daily capillary glucose tests (before meals, 1 and/or 2 h post meals, before driving, 
and before bed), and meticulous attention to adjusting insulin doses based on glucose levels, 
dietary intake and physical activity [4]. In addition, the physiological changes of pregnancy 
mean that insulin requirements are constantly changing, with most women needing higher 
doses initially, followed by insulin dose reduction in the late first trimester (typically 10–
16 weeks), and then a progressive increase from 20–24 weeks onwards [33]. As pregnancy 
advances, there is diminished skeletal muscle uptake of glucose, leading to maternal 
hyperglycaemia, and providing more glucose to the growing fetus [34]. The complexity of 
insulin dose adjustment is further complicated by the pharmacological limitations of insulin. 
There is a slower time to peak plasma concentration of insulin and more day-to-day 
variability in insulin pharmacokinetics in late pregnancy [34,35]. While fast-acting insulin 
analogues (Aspart, Humalog) should be injected at least 15 min before eating, the 
considerably slower absorption in late pregnancy means that even earlier pre-meal boluses 
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are advised. For many pregnant women, this means injecting 30–60 min before eating in late 
gestation. In clinical practice, continuous glucose monitoring (CGM) provides more 
confidence for earlier pre-meal bolusing and immediate feedback on the success, or not, of 
insulin dosing decisions. 
 
In a randomized controlled trial across 31 international centres, women using CGM had only 
slightly lower HbA1c levels [2 mmol/mol (0.2%)] compared with the capillary glucose 
monitoring group, but spent an additional 100 min per day with glucose levels in the target 
range [36]. This was achieved without increasing hypoglycaemia or insulin dose. The 
findings were consistent across clinics and comparable in insulin pump and MDI users. 
Taken together, these data suggest that more information about their glucose levels helped 
women with their daily insulin dosing and diabetes self-management decisions. Importantly, 
even these modest improvements in maternal glucose control, were associated with a 
substantial reduction in neonatal complications. Infants of mothers using CGM had 
significantly lower rates of large for gestational age, fewer neonatal intensive care unit 
(NICU) admissions, fewer episodes of neonatal hypoglycaemia and a 1-day shorter length of 
hospital stay [36]. The number of women needed to treat with CGM to prevent a neonatal 
complication was six for large for gestational age and neonatal hypoglycaemia and eight for 
NICU admission. Women started CGM at 12 ± 2 weeks’ gestation, meaning that continuous 
use until delivery required ~ 6–7 months of CGM. Given the high NHS costs of NICU 
admission, particularly among preterm infants, and the shorter duration of in-hospital care, 
the cost of CGM use during pregnancy (~ £210/month for the sensors used in our trial) will, 
at least in part, be offset by the potential neonatal healthcare savings. The next generation 
real-time CGM sensors are expected to have a longer lifespan (7–10 days), which will further 
reduce the costs. It is not known whether the more affordable Freestyle Libre system with a 
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14-day lifespan, but without alarms or alerts to warn of impending out of range glucose 
levels, will also be effective. 
In the setting of this randomized controlled trial, with motivated participants and clinics, the 
level of glucose control achieved was still suboptimal. Women in the standard care group 
using pumps or MDI achieved on average only 60% time-in-target (14.4 h/day) by 34 weeks’ 
gestation. The CGM group using MDI achieved the highest overall time-in-target (69% or 
16.6 h/day), while the CGM group using insulin pump therapy spent 66% time-in-target 
(15.8 h/day), suggesting that optimal glucose control remains elusive even with today’s most 
advanced diabetes technology. The time spent with hypoglycaemia and rates of maternal 
hypoglycaemia were very low, suggesting that modern insulin analogues have been very 
helpful for minimizing hypoglycaemia, but postprandial hyperglycaemia remains the major 
obstacle to optimal glucose control. Further analysis of maternal dietary intake may help us 
understand if there are particular dietary approaches that can help to minimize post-meal 
hyperglycaemia. 
Although not yet routinely available, closed-loop systems linking CGM with insulin delivery, 
offer the potential for glucose responsive, automated insulin delivery (Fig. 3). Although pre-
meal boluses are still required, because of the longer insulin absorption time, hybrid closed-
loop systems will adapt basal-insulin delivery according to post-meal glucose levels. 
Experiences from running an overnight study of closed-loop in pregnancy suggested that 
women were more confident giving larger insulin doses, particularly before their evening 
meal with the knowledge that closed-loop would minimize the risk of nocturnal 
hypoglycaemia by suspending insulin delivery if glucose levels were low or approaching low 
levels [37,38]. Many women, including those without clear biomedical benefit, describe 
feeling better and ‘more normal’ on wakening up in the morning, with an in-target glucose 
level [38]. Importantly, as for CGM, there was no difference in the treatment effect of closed-
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loop, between women using insulin pumps and MDI at enrolment. Larger randomized trials 
of longer duration and in diverse populations of pregnant women are needed to evaluate 
whether automated insulin delivery systems can improve glucose control and neonatal health 
outcomes. Given the pharmacokinetic limitations of currently available insulin analogues and 
the issues associated with subcutaneous insulin delivery, closed-loop systems will be unable 
to achieve 90–100% time-in-target during pregnancy. However, closed-loop systems provide 
the best potential option for consistently achieving 70–80% time in target for a broad range of 
pregnant women. As device usability improves, closed-loop systems may help to minimize 
the impact of social disadvantage and clinic-to-clinic variations, providing personalized 
glucose-responsive insulin delivery, during pregnancy and delivery, when it matters most for 
mothers and their babies. 
<H1>Interpregnancy care 
There is scope for improving the high rate of recurrence of adverse outcome by improving 
the transition between postnatal support and discussion, and preparation for a further 
pregnancy. In recent years, there has been growing awareness of the bereavement process 
following miscarriage and stillbirth. Qualitative research has illuminated parents’ experiences 
and highlighted the importance of interactions with healthcare professionals [39]. However, 
evidence to support specific interventions is sparse and generally of poor quality. This partly 
reflects the difficulty of conducting trials or other rigorous evaluations in this sensitive area 
[40]. Good practice guidance for health professionals has been developed by Sands, the 
stillbirth and neonatal charity [41]. This emphasizes sensitive and informed postnatal follow 
up appointments and training for healthcare professionals in supporting grieving parents. 
Another area which has been highlighted is the need for additional support in subsequent 
pregnancies [42]. 
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One area, which remains controversial, and is particularly pertinent to women with diabetes, 
is the timing of any subsequent pregnancy. In the past, it was often considered that after a 
pregnancy loss the best remedy was a rapid ‘replacement’ pregnancy. More recently, medical 
advice has suggested a delay for physical and emotional recovery, with WHO recommending 
a delay of at least 6 months after a miscarriage. However, a recent meta-analysis concluded 
that there was no evidence to support such a delay [43]. It is appreciated that a personalized 
approach is needed. Nevertheless, studies show that most women who experience a 
pregnancy loss will become pregnant again, many within 12 months [44]. Parents may seek 
information from health professionals about the optimal timing of a subsequent pregnancy, 
but can receive conflicting advice. Qualitative research with parents shows that many 
consider a further pregnancy very quickly, sometimes within days of a loss, although 
decisions to proceed may vary. One study found that fathers may be more reluctant than 
mothers to embark on a further pregnancy [42]. Although the decision about whether and 
when to proceed with a further pregnancy is a personal one, parents require evidence-based 
information about risks of recurrence and how to minimize those risks. 
No previous studies in this area have a specific focus on the experience of women with 
diabetes. Furthermore, NICE guidance for the management of diabetes in pregnancy did not 
consider care after an adverse pregnancy outcome [4]. Given the strong association of 
adverse outcomes with modifiable factors such as glycaemic control and high-dose folate, 
there is a clear need for care in the postnatal period to co-ordinate with postnatal 
contraception and/or support for preparation for pregnancy [45]. Skilful communication is 
needed to achieve this sensitively and to support parents to come to their own decisions. 
Suboptimal glycaemic control is a key factor driving the excess risk of fetal loss and 
congenital anomalies, and therefore in theory, interpregnancy improvements in glycaemic 
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control, and attention to optimizing other risk factors, could help to reduce risks in 
subsequent pregnancies. 
<H1>Developing an approach to improving outcomes 
The increasing participation in NPID allows unit-by-unit comparison in key pregnancy 
preparation and outcome measures. This, coupled with accurate demographic data, offers the 
opportunity to develop networks locally and nationally. Some of these will involve access to 
better and more consistent pre- and post-pregnancy information in primary care, through 
social media, or through incorporation into education programmes for women with diabetes. 
Others will require engagement with local communities, clear referral pathways to specialist 
teams before pregnancy, and leadership and coordination across public health, primary care, 
maternity and diabetes services at national, regional and local levels. While NPID documents 
the challenges, there are also opportunities to learn from successful practice. 
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FIGURE 1. Variation in the percentage of women taking 5mg folic acid before conception in 
individual units. The top panel shows the median (IQR) percentage of women with Type 1 
diabetes taking 5mg folic acid in individual clinics. The bottom panel shows the median 
(IQR) percentage of women with Type 2 diabetes taking 5mg folic acid in individual clinics. 
FIGURE 2. Variation in the percentage of women achieving the NICE recommended target 
HbA1c levels of < 48 mmol/mol (6.5%) after 24 weeks gestation in individual units. The top 
panel shows the median (IQR) percentage of women with Type 1 diabetes achieving HbA1c 
< 48 mmol/mol (6.5%) in late pregnancy. The bottom panel shows the median (IQR) 
percentage of women with Type 2 diabetes achieving HbA1c < 48 mmol/mol (6.5%) in late 
pregnancy. Data are included only from 126 units with at least 10 valid HbA1c measurements 
for Type 1 diabetes and 103 units for Type 2 diabetes units. 
FIGURE 3. A pregnant woman with Type 1 diabetes wearing the closed-loop system 
consisting of an insulin pump, continuous glucose monitor and a control algorithm housed on 
a mobile phone. 
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Table 1 National Pregnancy in Diabetes (NPID) audit data, collected from 172 maternity units during 2016  
 
 All Type 1 
diabetes 
Type 2 
diabetes 
Other* 
Women 3297 1618 1608 71 
Pregnancies 3304 1623 1610 71 
Total pregnancy outcomes† 3356 1650 1633 73 
Pregnancies ongoing after 24 weeks 3091 1506 1517 68 
Live Births after 24 weeks 3108 1517 1521 70 
Stillbirth 32 16 16 0 
Babies born after 24 weeks 3140 1533 1537 70 
Livebirths before 24 weeks 5 1 4 0 
Neonatal deaths 31 10 21 0 
Total registered births 2908 1492 1330 86 
 
*Type of diabetes was not specified (n = 28), specified as monogenic (n = 33) or other (n = 10). 
†Seven women had two pregnancies and there were 49 twin and 1 triplet pregnancies recorded among 3297 
women, providing outcome data for 3356 pregnancies. 
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